About REGENXBIO Inc.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
|
|
|
11-50 employees
View all REGENXBIO Inc. employees
|
|
Biotechnology
|
|
9804 Medical Center Dr, Rockville, Maryland 20850, US
|
|
2008
|
|
Biotechnology, Gene Therapy, Biopharmaceuticals
|
REGENXBIO Inc. Alternatives
Frequently Asked Questions about REGENXBIO Inc.
Emma A is the CEO of REGENXBIO Inc.. To contact Emma A email at [email protected].
The decision makers in REGENXBIO Inc. are Craig Malzahn, Francesca Cook, Jerome Jackson, etc. Click to Find REGENXBIO Inc. decision makers emails.
REGENXBIO Inc. Staff Directory
Search REGENXBIO Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
